Sponsored

Radiopharm Theranostics (ASX: RAD) welcomes study supporting Terbium-161 radiotherapeutics as promising cancer treatment candidate - Kalkine Media

February 29, 2024 11:05 AM AEDT | By Sonal Goyal
Follow us on Google News:https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • Schaefer-Schule et al has published results of a study involving six metastatic castration-resistant prostate cancer patients treated with 161Tb vs 177Lu.
  • The study validated RAD’s leadership in advancing Tb-161 radiotherapeutics targeting advanced cancer.
  • Partnership with TerThera makes RAD the first public company with access to Tb-161 for the development of multiple programs.

Radiopharm Theranostics Limited (ASX: RAD) has hailed a study indicating Terbium-161 radiotherapeutics as a promising treatment for advanced cancers.

The publication on the results of six metastatic Castration-Resistant Prostate Cancer (mCRPC) patients treated with 161Tb vs 177Lu has been made by Schaefer-Schuler et al.

The publication of first head-to-head pilot study suggests the leadership of RAD in developing first-in-class Terbium-161 (Tb-161) radiotherapeutics for treating prostate cancer.

Tb-161 - a promising candidate for advanced cancers

The findings of the study indicated that in comparison to 177Lu-PSMA-617, 161Tb-PSMA-617 provides significantly higher tumor-absorbed doses. Meanwhile, the absorbed doses of the relevant organs at risk were only marginally higher.

On average, a radiation dose delivered to tumor lesions by 161Tb-PSMA-617 is 2.4 times more than 177Lu-PSMA-617. These results strongly endorse Terbium-161 (Tb-161) as a promising candidate for radiotherapeutic targeting advanced cancer treatment.

About Tb-161

Data source: Company update

Notably, Tb-161 has demonstrated excellent bioequivalence, showcasing a biodistribution comparable to currently employed radiopharmaceuticals. Its potential superiority over Lutetium-177 may be attributed to the Auger effect, enhancing potency and efficacy by selectively eradicating tumor cells while leaving surrounding healthy tissue unaffected to a significant extent.

Robust Pipeline of RAD

The company’s innovative pipeline comprises two radiotherapeutics based on Tb-161 – RAD 402 and 502. RAD 402 targets advanced prostate cancer, while RAD 502 targets osteosarcoma. Tb-161 will be linked to two proprietary monoclonal antibodies for both assets.

In August 2023, the company inked an agreement with TerThera to secure the supply of Tb-161, a relatively scarce isotope. RAD highlighted that it is the first public company across the globe with access to Tb-161 for clinical development of multiple assets (as per the publicly available data).

RAD shares traded at AU$0.059 apiece at the time of writing on 29 February 2024.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.



Top ASX Listed Companies


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.